Chemotherapy Extravasation — Part 2: Recognition, Immediate Management, and Antidote Protocols

1. Signs and Symptoms of Extravasation

Early recognition of extravasation is the single most important factor in determining outcome. The severity of tissue injury correlates directly with the volume of drug that escapes the vascular compartment, the vesicant potential of the agent, the concentration of the drug, and the duration of tissue exposure.¹² Clinicians must be familiar with both early and late signs of extravasation and must distinguish extravasation from other infusion-related complications.

1.1 Early Signs and Symptoms

The following signs and symptoms may present during or immediately after chemotherapy infusion and should prompt immediate investigation for possible extravasation:¹²³

1.2 Late Signs and Symptoms

Late signs develop hours to days (or, for some DNA-binding vesicants, weeks) after the extravasation event:¹²

1.3 Central Venous Access Device Extravasation Signs

Extravasation from central venous access devices may present differently from peripheral extravasation and may be more difficult to detect:²⁴

1.4 Differential Diagnosis

The following conditions may mimic extravasation and should be considered in the differential:¹³

2. Immediate Management Algorithm

When extravasation is suspected or confirmed, the following standardized steps should be initiated immediately. This algorithm is consistent with recommendations from multiple international expert panels and guideline committees.¹²³⁵⁶

Step 1: Stop the Infusion Immediately

• Stop the infusion at once
• Do NOT remove the catheter/needle yet
• Do NOT flush the line
• Do NOT apply pressure to the site

Step 2: Aspirate Residual Drug

• Using a syringe attached to the catheter hub, attempt to aspirate as much of the extravasated drug and blood as possible
• Aspiration volume is typically limited (0.1–3 mL), but any drug removed reduces tissue exposure
• If using a peripheral IV: aspirate through the existing catheter
• If using a CVAD: aspirate through the device

Step 3: Remove the Catheter/Needle

• After aspiration attempts, carefully remove the peripheral catheter or Huber needle (for ports)
• For tunneled catheters and PICCs, do NOT remove the device without physician consultation, as removal may require specific procedures
• Apply gentle, sterile pressure to the site to prevent bleeding but avoid compressing the extravasated area

Step 4: Outline the Affected Area

• Using a skin marker, outline the borders of the visible swelling, erythema, and/or induration
• Record the estimated area (in cm) for comparison at follow-up assessments
• If possible, photograph the site (per institutional policy)

Step 5: Identify the Extravasated Agent

• Confirm the drug name, concentration, estimated volume extravasated, and drug classification (vesicant, irritant, non-vesicant)
• This determination drives all subsequent management decisions

Step 6: Administer the Appropriate Antidote

• Select the antidote based on the agent classification (see Section 3 below)
• Administer the antidote as soon as possible; efficacy decreases with delay

Step 7: Apply Thermal Management

• Select warm or cold compresses based on the agent class (see Section 4 below)
• Apply for the specified duration

Step 8: Elevate the Affected Extremity

• Elevate the extremity above heart level to promote venous and lymphatic drainage
• Maintain elevation for 24–48 hours

Step 9: Notify the Physician/Provider

• Notify the prescribing physician or oncologist immediately
• Request surgical consultation if indicated (see Part 3, Section 1)

Step 10: Document the Event

• Complete standardized extravasation documentation (see Part 3, Section 3)

Step 11: Arrange Follow-Up

• Schedule wound assessment within 24 hours
• Provide patient with written instructions and contact information

3. Specific Antidote Protocols

3.1 Dexrazoxane for Anthracycline Extravasation

Dexrazoxane is the only agent with regulatory approval (FDA, EMA) as a specific antidote for anthracycline extravasation. It is approved for the treatment of extravasation resulting from intravenous administration of anthracycline chemotherapy agents. Dexrazoxane acts as a catalytic inhibitor of topoisomerase II and also chelates iron, reducing the formation of anthracycline-iron free radical complexes that cause tissue oxidative damage.⁷⁸

Indications:

• Extravasation of doxorubicin, daunorubicin, epirubicin, or idarubicin
• May be considered for mitoxantrone extravasation (off-label; limited data)

Dosing Protocol:

Maximum single dose: 2,000 mg (regardless of body surface area)

Administration details:

• Administer as an intravenous infusion over 1–2 hours
• Infuse into a DIFFERENT extremity or via a central line in a DIFFERENT vein than the extravasation site
• Reconstitute and dilute according to the manufacturer’s instructions (typically reconstituted in the provided diluent, then diluted in 0.9% sodium chloride or lactated Ringer’s solution to a concentration of 1.3–5 mg/mL)
• Begin infusion as soon as possible; ideally within 6 hours of the extravasation event. The time window is critical — efficacy decreases significantly beyond 6 hours

Dose adjustment for renal impairment:

Contraindications and precautions:

• Do NOT use dexrazoxane concurrently with DMSO for the same extravasation event (DMSO may reduce dexrazoxane efficacy)¹
• Do NOT apply ice or cold compresses during the dexrazoxane treatment period (remove cold packs at least 15 minutes before dexrazoxane infusion and do not reapply during the 3-day treatment course)
• Dexrazoxane is itself myelosuppressive; monitor complete blood counts. Patients who are receiving concurrent myelosuppressive chemotherapy should be aware that dexrazoxane may exacerbate myelosuppression
• Pregnancy category D — assess pregnancy status before administration
• Hepatotoxicity has been reported; monitor liver function
• Dexrazoxane may impair wound healing

Adverse effects:

• Nausea, vomiting, diarrhea
• Myelosuppression (leukopenia, thrombocytopenia)
• Elevated hepatic transaminases
• Injection site reactions (when administered through the treatment vein — which should be avoided)
• Fatigue

Evidence basis: Two prospective, multicenter, single-arm studies demonstrated that dexrazoxane prevented surgical intervention in 98% of patients with anthracycline extravasation and prevented tissue necrosis in 95% of patients when administered within 6 hours of the event.⁷

3.2 Hyaluronidase for Vinca Alkaloid and Taxane Extravasation

Hyaluronidase is a spreading enzyme that temporarily degrades hyaluronic acid in the interstitial space, facilitating the dispersion and absorption of the extravasated drug across a larger tissue area, thereby reducing local concentration and tissue damage.¹²³

Indications:

• Extravasation of vinca alkaloids: vincristine, vinblastine, vindesine, vinflunine, vinorelbine
• Extravasation of taxanes: paclitaxel (large-volume extravasation), docetaxel (if treated as vesicant)
• May also be used for etoposide or teniposide extravasation (some panels recommend)

Dosing Protocol:

Contraindications and precautions:

• Known hypersensitivity to hyaluronidase or bovine proteins (for bovine-derived formulations)
• Do not inject into infected or inflamed areas (other than the extravasation itself)
• Do NOT use hyaluronidase for DNA-binding vesicant extravasation (anthracyclines, mechlorethamine) — spreading the drug would worsen tissue damage
• Recombinant human hyaluronidase may be used in patients with bovine protein sensitivity

Adverse effects:

• Local injection site reactions (pain, swelling)
• Allergic reactions (rare, more common with bovine-derived products)
• Urticaria (rare)

3.3 Sodium Thiosulfate for Mechlorethamine (Nitrogen Mustard) Extravasation

Sodium thiosulfate acts as a chemical neutralizer, inactivating mechlorethamine through an alkylation reaction that renders the drug non-toxic to tissue.¹²⁹

Indications:

• Extravasation of mechlorethamine (nitrogen mustard)
• May also be used for concentrated cisplatin extravasation (>0.4 mg/mL) — off-label but supported by some expert panels¹

Dosing Protocol:

Contraindications and precautions:

• Known hypersensitivity to sodium thiosulfate
• Large subcutaneous volumes may cause tissue distension — inject slowly and distribute across multiple sites
• Assess for allergic reaction during and after administration

Adverse effects:

• Local pain at injection sites
• Tissue distension from injected volume

3.4 Topical DMSO (Dimethyl Sulfoxide) for Vesicant Extravasation

DMSO is a solvent with anti-inflammatory and free radical scavenging properties that enhances tissue penetration. Topical application is thought to facilitate systemic absorption of the extravasated drug away from the local injury site while simultaneously reducing inflammatory tissue damage.¹²¹⁰

Indications (per the European expert panel and the supportive care expert group):

• Extravasation of anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin) — ONLY when dexrazoxane is not available or cannot be administered within the required 6-hour window
• Extravasation of mitomycin C
• Extravasation of mitoxantrone
• Extravasation of dactinomycin (actinomycin D)
• Some panels recommend DMSO for platinum compound extravasation (cisplatin, carboplatin, oxaliplatin)

CRITICAL NOTE: Dexrazoxane and DMSO must NOT be used concurrently for the same extravasation event. When dexrazoxane is available and can be administered within 6 hours, it is the preferred antidote for anthracycline extravasation based on stronger clinical evidence. DMSO is considered an alternative when dexrazoxane is unavailable, contraindicated, or the 6-hour window has passed.¹⁸

Dosing Protocol:

Contraindications and precautions:

• Do NOT use concurrently with dexrazoxane (for the same event)
• Do NOT apply an occlusive dressing over DMSO — allow to air-dry
• May cause local skin irritation, burning, or a garlic-like odor and taste (patients should be warned)
• Avoid contact with latex gloves — DMSO can dissolve latex. Use nitrile or polyethylene gloves
• DMSO is a potent solvent and can enhance the percutaneous absorption of other topically applied substances — do not apply other topical agents to the area concurrently unless specifically directed

Adverse effects:

• Local burning, stinging, or itching at the application site
• Characteristic garlic-like taste and body odor (occurs because DMSO is partially metabolized to dimethyl sulfide, which is excreted through the lungs and skin)
• Erythema or local skin irritation
• Rarely: allergic contact dermatitis

3.5 Antidote Summary by Agent Class

4. Thermal Management Protocols

The application of thermal modalities (warm or cold compresses) is a component of extravasation management supported by expert consensus, although the evidence base is largely derived from case reports, case series, and animal studies.¹²³

4.1 Cold Compresses (Localize and Slow Absorption)

Mechanism: Cold application causes local vasoconstriction, which limits the spread of the extravasated drug into surrounding tissue, reduces local metabolism and inflammation, and may slow cellular uptake of the agent.

Indicated for:

• DNA-binding vesicants: anthracyclines (when dexrazoxane is NOT being administered), mechlorethamine, mitomycin C, dactinomycin, trabectedin
• Most irritant agents
• Platinum compounds

Application protocol:

4.2 Warm Compresses (Disperse and Enhance Absorption)

Mechanism: Warm application causes local vasodilation, which increases local blood flow and promotes dispersion, dilution, and systemic absorption of the extravasated drug away from the injury site.

Indicated for:

• Non-DNA-binding vesicants: vinca alkaloids (vincristine, vinblastine, vindesine, vinflunine, vinorelbine)
• Taxanes (paclitaxel, docetaxel, cabazitaxel) — per most expert panels

Application protocol:

4.3 Thermal Management Decision Algorithm

Is the extravasated agent a vinca alkaloid or taxane?
  ├── YES → Apply WARM compresses (+ hyaluronidase)
  └── NO
       ├── Is the extravasated agent an anthracycline?
       │    ├── YES → Is dexrazoxane being administered?
       │    │    ├── YES → NO thermal application during dexrazoxane treatment
       │    │    └── NO → Apply COLD compresses (+ DMSO if available)
       │    └──
       ├── Is the extravasated agent mechlorethamine?
       │    └── YES → Apply COLD compresses (+ sodium thiosulfate)
       ├── Is the extravasated agent mitomycin C, dactinomycin, or trabectedin?
       │    └── YES → Apply COLD compresses (+ DMSO for mitomycin C and dactinomycin)
       └── Is the extravasated agent an irritant or other agent?
            └── YES → Apply COLD compresses; elevate extremity

5. Management of Irritant Extravasation

While irritant agents carry a lower risk of tissue necrosis than vesicants, appropriate management is still warranted, particularly for large-volume extravasation:¹²

General Management Steps for Irritant Extravasation

1. Stop the infusion immediately
2. Attempt to aspirate residual drug through the existing catheter
3. Remove the catheter
4. Apply cold compresses intermittently for 15–20 minutes, 4 times daily, for 24–48 hours
5. Elevate the extremity
6. No specific antidote is generally required for irritant extravasation
7. Assess and document the site
8. Monitor the site over the following 48–72 hours for worsening symptoms
9. If symptoms worsen or tissue necrosis develops, manage as a vesicant extravasation and consult surgery

Special Considerations for Specific Irritants

6. Management of Non-Vesicant Extravasation

Extravasation of non-vesicant agents generally requires minimal intervention but should still be documented:¹

1. Stop the infusion
2. Remove the catheter
3. Apply cold or warm compresses for comfort as needed
4. Elevate the extremity
5. Reassure the patient
6. Document the event
7. Restart the infusion in a different vein if the treatment needs to continue
8. Monitor the site for 24–48 hours; worsening symptoms are unexpected and should prompt reassessment

7. Managing Extravasation with Unknown Agent Volume

In clinical practice, the exact volume of extravasated drug is rarely known. The following approach is recommended when the volume is uncertain:²³

1. Assume the worst-case scenario and manage according to the agent’s classification
2. For vesicants, administer the full antidote protocol regardless of suspected volume
3. Document the estimated volume based on:
   • Infusion rate and estimated time since last site assessment
   • Visible swelling and area of induration
   • Amount of drug aspirated from the catheter
4. Clinical judgment regarding the severity of signs and symptoms should guide the aggressiveness of management

8. Extravasation During Concurrent Multi-Agent Infusions

When extravasation occurs during a multi-agent chemotherapy regimen administered through the same intravenous line:²

1. Stop all infusions immediately
2. Identify ALL agents that may have extravasated
3. If one of the agents is a vesicant, manage according to the vesicant protocol
4. If agents require conflicting antidotes (e.g., one agent requires cold and another requires warm compresses), prioritize the management of the agent with the highest tissue-damage potential
5. Dexrazoxane takes precedence if any anthracycline is among the extravasated agents
6. Document all agents that may have been involved

References